drugset / Trial / NCT04959812

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

NCT04959812

Phase 1/2 Completed 46 enrolled University of Texas Southwestern Medical Center
RandomizedCrossoverSingle-blindBasic science

Summary

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

Timeline

Start
2022-03-01
Primary completion
2023-09-08
Completion
2023-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 30 ug Subcutaneous

Indications

No indication recorded.